CoChat

Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS

The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.

Abstract

Calcitonin was discovered as a hypocalcemic principal that was initially thought to originate from the parathyroid gland. This view was corrected subsequently, and an origin from the thyroid C cells was documented. The purification and sequencing of various calcitonins soon followed. Calcitonin is a 32-amino-acid-long peptide with an N-terminal disulfide bridge and a C-terminal prolineamide residue. The peptide was shown to potently inhibit bone resorption; however, a direct osteoclastic action of the peptide was confirmed only in the early 1980s. Several osteoclast calcitonin receptors have subsequently been cloned and sequenced. Specific regions of the receptor necessary for ligand binding and intracellular signaling through cyclic AMP and calcium have been identified through systematic deletion mutagenesis and chimeric receptor studies. Calcitonin's potent antiresorptive effect has led to its use in treating Paget's disease of bone, osteoporosis, and hypercalcemia. This review retraces key aspects of the synthesis and structure of calcitonin, its cellular and molecular actions, and its therapeutic uses as they have emerged over the 40 years since its discovery. The review also examines the implications of these findings for future clinical applications as a tribute to early workers to whom credit must be given for creation of an important and expanding field. Notable are the new approaches currently being used to enhance calcitonin action, including novel allosteric activa…

Overview

Integrity signals

Registry

Crossref · 10.1016/s8756-3282(02)00688-9

Cites

189 of 189 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 189 references

Research works printed but not linked: 2

  1. Kumar, 1963, Further evidence for calcitonin, Lancet, ii, 480
  2. Schiraldi, 1987, Salmon calcitonin in cancer pain, Int J Clin Pharmacol Therapy Toxicol, 25, 229

Cited by

See all 151

Metadata

Authors
Zaidi, M., Inzerillo, A. M., Moonga, B. S., Bevis, P. J. R., & Huang, C. L.-H.
Affiliations
  • Mount Sinai Hospital (US)
  • University of Cambridge (GB)
Corresponding author
Zaidi, M
Venue
Bone
Publisher
Elsevier BV
Published
2002-05
Volume
30
Issue
5
Pages
655-663
ISSN
  • 1873-2763 (ISSN-L)
  • 8756-3282
OpenAlex
W2058666456
Cited by
151
References
189
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 7 · 2019: 10 · 2018: 6 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 6 · 2013: 4 · 2012: 4
FWCI
0.75
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Bone (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (R01 AG 14917-06, R01AG014917)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
calcitonin, calcitonin receptor, bone resorption inhibition, osteoclasts, thyroid C cells, parathyroid glands, cAMP signaling, Paget's disease of bone, osteoporosis, hypercalcemia, calcimimetics
MeSH terms
Bone and Bones, Bone Diseases, Calcitonin, Calcium, Humans, Bone Remodeling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS. https://app.cochat.ai/papers/10.1016/s8756-3282(02)00688-9
The paper
Zaidi, M., Inzerillo, A. M., Moonga, B. S., Bevis, P. J. R., & Huang, C. L.-H. (2002). Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS. Bone. https://doi.org/10.1016/s8756-3282(02)00688-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.